BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8774616)

  • 1. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
    Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
    Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T; Góra-Tybor J; Lech-Marańda E; Błoński JZ; Kasznicki M
    Eur J Haematol; 2001 Mar; 66(3):188-94. PubMed ID: 11350487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine in the treatment of chronic lymphocytic leukemia.
    Robak T
    Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma.
    Róbak T; Gora-Tybor J; Krykowski E; Walewski JA; Borawska A; Pluźańska A; Potemski P; Hellmann A; Zaucha JM; Konopka L; Ceglarek B; Durźyński T; Sikorska A; Michalak K; Urasiński J; Opalińska J; Dmoszyńska A; Adamczyk-Cioch MB; Kuratowska Z; Dwilewicz-Trojaczek J; Boguradzki P; Deren M; Maj S; Grieb P
    Leuk Lymphoma; 1997 Jun; 26(1-2):99-105. PubMed ID: 9250793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
    Robak T; Błasinka-Morawiec M; Krykowski E; Kasznicki M; Płuzanska A; Potemski P; Hellmann A; Zaucha JM; Lewandowski K; Dmoszynska A; Hansz J; Komarnicki M; Konopka L; Durzynski T; Ceglarek B; Sikorska A; Kotlarek-Haus S; Mazur G; Urasinski I; Zdziarska B; Maj S; Kopec I; Skotnicki AB; Dwilewicz-Trojaczek J; Grieb P
    Leuk Lymphoma; 1996 Aug; 22(5-6):509-14. PubMed ID: 8882965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
    Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
    J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
    Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
    Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
    Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
    J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).
    Delannoy A; Martiat P; Gala JL; Deneys V; Ferrant A; Bosly A; Schieff JM; Michaux JL
    Leukemia; 1995 Jul; 9(7):1130-5. PubMed ID: 7630184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Beksaç M; Arat M; Idilman R
    Cancer; 1999 Jan; 85(1):242-3. PubMed ID: 9921999
    [No Abstract]   [Full Text] [Related]  

  • 12. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma.
    Tulpule A; Schiller G; Harvey-Buchanan LA; Lee M; Espina BM; Khan AU; Boswell W; Nathwani B; Levine AM
    Cancer; 1998 Dec; 83(11):2370-6. PubMed ID: 9840537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
    Betticher DC; Ratschiller D; Hsu Schmitz SF; von Rohr A; Hess U; Zulian G; Wernli M; Tichelli A; Tobler A; Fey MF; Cerny T
    Ann Oncol; 1998 Jul; 9(7):721-6. PubMed ID: 9739437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
    Tondini C; Balzarotti M; Rampinelli I; Valagussa P; Luoni M; De Paoli A; Santoro A; Bonadonna G
    Ann Oncol; 2000 Feb; 11(2):231-3. PubMed ID: 10761763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma.
    Robak T; Lech-Maranda E; Janus A; Blonski J; Wierzbowska A; Gora-Tybor J
    Leuk Lymphoma; 2007 Jun; 48(6):1092-101. PubMed ID: 17577772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
    Liliemark J; Martinsson U; Cavallin-Ståhl E; Svedmyr E; Porwit A; Strömberg M; Juliusson G
    Leuk Lymphoma; 1998 Aug; 30(5-6):573-81. PubMed ID: 9711919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Tallman MS; Hakimian D; Zanzig C; Hogan DK; Rademaker A; Rose E; Variakojis D
    J Clin Oncol; 1995 Apr; 13(4):983-8. PubMed ID: 7707127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
    Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
    Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
    Kong LR; Huang CF; Hakimian D; Variakojis D; Klein L; Kuzel TM; Gordon LI; Zanzig C; Wollins E; Tallman MS
    Cancer; 1998 Mar; 82(5):957-64. PubMed ID: 9486587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.